Metastatic Castration-resistant Prostate Cancer Clinical Trials in Cleveland, Ohio

7 studies are recruiting for metastatic castration-resistant prostate cancer in Cleveland, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

    The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Cleveland, Ohio
    Locations
    132 in total
    Run by
    AstraZeneca

    See if you can join NCT07611110 on ClinicalTrials.gov

  2. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, Ohio
    Locations
    33 in total
    Run by
    Parabilis Medicines, Inc.

    See if you can join NCT05919264 on ClinicalTrials.gov

  3. A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior secon…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University Hospitals Cleveland Medical Center, Cleveland, Ohio
    Locations
    23 in total
    Run by
    Kyntra Bio

    See if you can join NCT06842498 on ClinicalTrials.gov

  4. Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

    The purpose of this study is to find out what treatment works best for participants with metastatic prostate cancer that are not responding to hormone treatment and docetaxel and are also Prostate-specific membrane antigen(PSMA) positive.

    Stage
    Phase 2
    Ages
    19 and older
    Site
    Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio
    Run by
    Case Comprehensive Cancer Center

    See if you can join NCT06738303 on ClinicalTrials.gov

  5. The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

    The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University Hospital, Cleveland, Ohio
    Locations
    33 in total
    Run by
    Telix Pharmaceuticals (Innovations) Pty Limited

    See if you can join NCT06520345 on ClinicalTrials.gov

  6. Study With [225Ac]Ac-FL-020 in mCRPC Participants

    The purpose of this study is to evaluate the safety, therapeutic effect, and pharmacokinetics of [225Ac]Ac-FL-020 in participants with metastatic castration-resistant prostate cancer (mCRPC).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University Hospital of Cleveland, Cleveland, Ohio
    Locations
    11 in total
    Run by
    Full-Life Technologies UK Limited

    See if you can join NCT06492122 on ClinicalTrials.gov

  7. A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

    The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Research Site, Cleveland, Ohio
    Locations
    16 in total
    Run by
    AstraZeneca

    See if you can join NCT06879041 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.